Home/Pipeline/PSMA-Dex

PSMA-Dex

Prostate Cancer

Pre-clinicalActive

Key Facts

Indication

Prostate Cancer

Phase

Pre-clinical

Status

Active

Company

DexTech Medical

About DexTech Medical

DexTech Medical is a clinical-stage biotech developing targeted cancer therapies using its proprietary GuaDex platform, a carbohydrate-drug-conjugate technology. The company's pipeline includes several drug candidates, most notably OsteoDex for prostate cancer, which appears to be in advanced clinical studies. With a lean operational model, patented technology, and a focus on urological oncology, DexTech aims to address significant unmet medical needs in cancer treatment, though it faces the typical high-risk, high-cost challenges of drug development.

View full company profile

Therapeutic Areas

Oncology Urological Oncology

Other Prostate Cancer Drugs

Drug	Company	Phase	Status
APVO442	Aptevo Therapeutics	Preclinical	Active
APVO452	Aptevo Therapeutics	Discovery	Active
BIO 300	Humanetics Corp.	Not Specified	Active
Opaganib	RedHill Biopharma	Phase 2	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
CROES Registry	AngioDynamics	Post-Market Registry	Active
Cannabics® PRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC
HDP-103	Heidelberg Pharma	Preclinical	Active
ENV105	Kairos Pharma	Phase 2	Active
AI for Prostate Cancer	Invenio Imaging	Research	Active
Mitomic™ Test for Prostate Cancer	MDNA Life Sciences	Development/Validation	Active